866-997-4948(US-Canada Toll Free)

Korea Leukemia Therapeutics Market Research Report 2018

Published By :

QYResearch

Published Date : Jul 2018

Category :

Pharmaceutical

No. of Pages : 110 Pages

Korea plays an important role in global market, with market size of xx million USD in 2017 and will be xx million USD in 2025, with a CAGR of xx%.

This report studies the Leukemia Therapeutics development status and future trend in Korea, focuses on top players in Korea, also splits Leukemia Therapeutics by type and by Application, to fully and deeply research and reveal the market general situation and future forecast.

The major players in Korea market include
Roche
GlaxoSmithKline
Novartis
Bristol-Myers Squibb
Eisai
Biogen Idec
ERYtech Pharma
Celgene
Genmab
Cephalon
Clavis Pharma
Pfizer

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
Gleevec
Sprycel
Tasigna
Clolar
Others

On the basis of the end users/Application, this report covers
Hospital
Clinic

Table of Contents

Korea Leukemia Therapeutics Market Research Report 2018
1 Leukemia Therapeutics Overview
1.1 Product Overview and Scope of Leukemia Therapeutics
1.2 Classification of Leukemia Therapeutics by Product Category
1.2.1 Korea Leukemia Therapeutics Sales (K Units) Comparison by Type (2013-2025)
1.2.2 Korea Leukemia Therapeutics Sales (K Units) Market Share by Type in 2017
1.2.3 Gleevec
1.2.4 Sprycel
1.2.5 Tasigna
1.2.6 Clolar
1.2.7 Others
1.3 Korea Leukemia Therapeutics Market by Application/End Users
1.3.1 Korea Leukemia Therapeutics Sales (K Units) and Market Share Comparison by Application (2013-2025)
1.3.2 Hospital
1.3.3 Clinic
1.4 Korea Revenue and Sales of Leukemia Therapeutics (2013-2025)
1.4.1 Korea Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2025)
1.4.2 Korea Leukemia Therapeutics Revenue (Million USD) and Growth Rate (%)(2013-2025)

2 Korea Leukemia Therapeutics Market Competition by Players/Manufacturers
2.1 Korea Leukemia Therapeutics Sales (K Units) and Market Share (%) of Key Players/Manufacturers (2013-2018)
2.2 Korea Leukemia Therapeutics Revenue and Share by Players/Manufacturers (2013-2018)
2.3 Korea Leukemia Therapeutics Average Price (USD/Unit) by Players/Manufacturers (2013-2018)
2.4 Korea Leukemia Therapeutics Market Competitive Situation and Trends
2.4.1 Korea Leukemia Therapeutics Market Concentration Rate
2.4.2 Korea Leukemia Therapeutics Market Share of Top 3 and Top 5 Players/Manufacturers
2.4.3 Mergers & Acquisitions, Expansion in Korea Market
2.5 Korea Players/Manufacturers Leukemia Therapeutics Manufacturing Base Distribution, Sales Area, Product Type

3 Korea Leukemia Therapeutics Sales and Revenue (Value) by Type (2013-2018)
3.1 Korea Leukemia Therapeutics Sales (K Units) and Market Share by Type/ Product Category (2013-2018)
3.2 Korea Leukemia Therapeutics Revenue (Million USD) and Market Share by Type (2013-2018)
3.3 Korea Leukemia Therapeutics Price (USD/Unit) by Type (2013-2018)
3.4 Korea Leukemia Therapeutics Sales Growth Rate (%) by Type (2013-2018)

4 Korea Leukemia Therapeutics Sales by Application (2013-2018)
4.1 Korea Leukemia Therapeutics Sales (K Units) and Market Share by Application (2013-2018)
4.2 Korea Leukemia Therapeutics Sales Growth Rate (%) by Application (2013-2018)
4.3 Market Drivers and Opportunities

5 Korea Leukemia Therapeutics Players/Suppliers Profiles and Sales Data
5.1 Roche
5.1.1 Company Basic Information, Manufacturing Base and Competitors
5.1.2 Leukemia Therapeutics Product Category, Application and Specification
5.1.2.1 Product A
5.1.2.2 Product B
5.1.3 Roche Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
5.1.4 Main Business/Business Overview
5.2 GlaxoSmithKline
5.2.1 Company Basic Information, Manufacturing Base and Competitors
5.2.2 Leukemia Therapeutics Product Category, Application and Specification
5.2.2.1 Product A
5.2.2.2 Product B
5.2.3 GlaxoSmithKline Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
5.2.4 Main Business/Business Overview
5.3 Novartis
5.3.1 Company Basic Information, Manufacturing Base and Competitors
5.3.2 Leukemia Therapeutics Product Category, Application and Specification
5.3.2.1 Product A
5.3.2.2 Product B
5.3.3 Novartis Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
5.3.4 Main Business/Business Overview
5.4 Bristol-Myers Squibb
5.4.1 Company Basic Information, Manufacturing Base and Competitors
5.4.2 Leukemia Therapeutics Product Category, Application and Specification
5.4.2.1 Product A
5.4.2.2 Product B
5.4.3 Bristol-Myers Squibb Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
5.4.4 Main Business/Business Overview
5.5 Eisai
5.5.1 Company Basic Information, Manufacturing Base and Competitors
5.5.2 Leukemia Therapeutics Product Category, Application and Specification
5.5.2.1 Product A
5.5.2.2 Product B
5.5.3 Eisai Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
5.5.4 Main Business/Business Overview
5.6 Biogen Idec
5.6.1 Company Basic Information, Manufacturing Base and Competitors
5.6.2 Leukemia Therapeutics Product Category, Application and Specification
5.6.2.1 Product A
5.6.2.2 Product B
5.6.3 Biogen Idec Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
5.6.4 Main Business/Business Overview
5.7 ERYtech Pharma
5.7.1 Company Basic Information, Manufacturing Base and Competitors
5.7.2 Leukemia Therapeutics Product Category, Application and Specification
5.7.2.1 Product A
5.7.2.2 Product B
5.7.3 ERYtech Pharma Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
5.7.4 Main Business/Business Overview
5.8 Celgene
5.8.1 Company Basic Information, Manufacturing Base and Competitors
5.8.2 Leukemia Therapeutics Product Category, Application and Specification
5.8.2.1 Product A
5.8.2.2 Product B
5.8.3 Celgene Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
5.8.4 Main Business/Business Overview
5.9 Genmab
5.9.1 Company Basic Information, Manufacturing Base and Competitors
5.9.2 Leukemia Therapeutics Product Category, Application and Specification
5.9.2.1 Product A
5.9.2.2 Product B
5.9.3 Genmab Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
5.9.4 Main Business/Business Overview
5.10 Cephalon
5.10.1 Company Basic Information, Manufacturing Base and Competitors
5.10.2 Leukemia Therapeutics Product Category, Application and Specification
5.10.2.1 Product A
5.10.2.2 Product B
5.10.3 Cephalon Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
5.10.4 Main Business/Business Overview
5.11 Clavis Pharma
5.12 Pfizer

6 Leukemia Therapeutics Manufacturing Cost Analysis
6.1 Leukemia Therapeutics Key Raw Materials Analysis
6.1.1 Key Raw Materials
6.1.2 Price Trend of Key Raw Materials
6.1.3 Key Suppliers of Raw Materials
6.1.4 Market Concentration Rate of Raw Materials
6.2 Proportion of Manufacturing Cost Structure
6.2.1 Raw Materials
6.2.2 Labor Cost
6.2.3 Manufacturing Expenses
6.3 Manufacturing Process Analysis of Leukemia Therapeutics

7 Industrial Chain, Sourcing Strategy and Downstream Buyers
7.1 Leukemia Therapeutics Industrial Chain Analysis
7.2 Upstream Raw Materials Sourcing
7.3 Raw Materials Sources of Leukemia Therapeutics Major Manufacturers in 2017
7.4 Downstream Buyers

8 Marketing Strategy Analysis, Distributors/Traders
8.1 Marketing Channel
8.1.1 Direct Marketing
8.1.2 Indirect Marketing
8.1.3 Marketing Channel Development Trend
8.2 Market Positioning
8.2.1 Pricing Strategy
8.2.2 Brand Strategy
8.2.3 Target Client
8.3 Distributors/Traders List

9 Market Effect Factors Analysis
9.1 Technology Progress/Risk
9.1.1 Substitutes Threat
9.1.2 Technology Progress in Related Industry
9.2 Consumer Needs/Customer Preference Change
9.3 Economic/Political Environmental Change

10 Korea Leukemia Therapeutics Market Size (Sales and Revenue) Forecast (2018-2025)
10.1 Korea Leukemia Therapeutics Sales (K Units), Revenue (Million USD) Forecast (2018-2025)
10.2 Korea Leukemia Therapeutics Sales (K Units) Forecast by Type (2018-2025)
10.3 Korea Leukemia Therapeutics Sales (K Units) Forecast by Application (2018-2025)

11 Research Findings and Conclusion

List of Table

List of Tables and Figures

Figure Korea Market Size (Million USD) Status and Outlook (2013-2025)
Table Leukemia Therapeutics Sales (K Units) and Revenue (Million USD) Market Split by Product Type
Table Leukemia Therapeutics Sales (K Units) by Application (2017-2025)
Figure Product Picture of Leukemia Therapeutics
Table Korea Leukemia Therapeutics Sales (K Units) and Growth Rate (%) Comparison by Type (Product Category) (2013-2025)
Figure Korea Leukemia Therapeutics Sales Volume Market Share by Type in 2017
Figure Gleevec Product Picture
Figure Sprycel Product Picture
Figure Tasigna Product Picture
Figure Clolar Product Picture
Figure Others Product Picture
Figure Korea Leukemia Therapeutics Sales (K Units) Comparison by Application (2013-2025)
Figure Korea Sales Market Share (%) of Leukemia Therapeutics by Application in 2017
Figure Hospital Examples
Figure Clinic Examples
Figure Korea Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2025)
Figure Korea Leukemia Therapeutics Revenue (Million USD) and Growth Rate (%)(2013-2025)
Table Korea Leukemia Therapeutics Sales of Key Players/Manufacturers (2013-2018)
Table Korea Leukemia Therapeutics Sales Share (%) by Players/Manufacturers (2013-2018)
Figure 2017 Korea Leukemia Therapeutics Sales Share (%) by Players/Manufacturers
Figure 2017 Korea Leukemia Therapeutics Sales Share (%) by Players/Manufacturers
Table Korea Leukemia Therapeutics Revenue by Players/Manufacturers (2013-2018)
Table Korea Leukemia Therapeutics Revenue Market Share (%) by Players/Manufacturers (2013-2018)
Figure 2017 Korea Leukemia Therapeutics Revenue Share (%) by Players/Manufacturers
Figure 2017 Korea Leukemia Therapeutics Revenue Share (%) by Players/Manufacturers
Table Korea Market Leukemia Therapeutics Average Price (USD/Unit) of Key Players/Manufacturers (2013-2018)
Figure Korea Market Leukemia Therapeutics Average Price (USD/Unit) of Key Players/Manufacturers in 2017
Figure Korea Leukemia Therapeutics Market Share of Top 3 Players/Manufacturers
Figure Korea Leukemia Therapeutics Market Share of Top 5 Players/Manufacturers
Table Korea Players/Manufacturers Leukemia Therapeutics Manufacturing Base Distribution and Sales Area
Table Korea Players/Manufacturers Leukemia Therapeutics Product Category
Table Korea Leukemia Therapeutics Sales (K Units) by Type (2013-2018)
Table Korea Leukemia Therapeutics Sales Share (%) by Type (2013-2018)
Figure Korea Leukemia Therapeutics Sales Share (%) by Type (2013-2018)
Figure Korea Leukemia Therapeutics Sales Market Share (%) by Type in 2017
Table Korea Leukemia Therapeutics Revenue (Million USD) and Market Share by Type (2013-2018)
Table Korea Leukemia Therapeutics Revenue Market Share (%) by Type (2013-2018)
Figure Revenue Market Share of Leukemia Therapeutics by Type (2013-2018)
Figure Revenue Market Share of Leukemia Therapeutics by Type in 2017
Table Korea Leukemia Therapeutics Price (USD/Unit) by Type (2013-2018)
Figure Korea Leukemia Therapeutics Sales Growth Rate (%) by Type (2013-2018)
Table Korea Leukemia Therapeutics Sales (K Units) by Application (2013-2018)
Table Korea Leukemia Therapeutics Sales Market Share (%) by Application (2013-2018)
Figure Korea Leukemia Therapeutics Sales Market Share (%) by Application (2013-2018)
Figure Korea Leukemia Therapeutics Sales Market Share (%) by Application in 2017
Table Korea Leukemia Therapeutics Sales Growth Rate (%) by Application (2013-2018)
Figure Korea Leukemia Therapeutics Sales Growth Rate (%) by Application (2013-2018)
Table Roche Leukemia Therapeutics Basic Information List
Table Roche Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure Roche Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2018)
Figure Roche Leukemia Therapeutics Sales Market Share (%) in Korea (2013-2018)
Figure Roche Leukemia Therapeutics Revenue Market Share (%) in Korea (2013-2018)
Table GlaxoSmithKline Leukemia Therapeutics Basic Information List
Table GlaxoSmithKline Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure GlaxoSmithKline Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2018)
Figure GlaxoSmithKline Leukemia Therapeutics Sales Market Share (%) in Korea (2013-2018)
Figure GlaxoSmithKline Leukemia Therapeutics Revenue Market Share (%) in Korea (2013-2018)
Table Novartis Leukemia Therapeutics Basic Information List
Table Novartis Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure Novartis Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2018)
Figure Novartis Leukemia Therapeutics Sales Market Share (%) in Korea (2013-2018)
Figure Novartis Leukemia Therapeutics Revenue Market Share (%) in Korea (2013-2018)
Table Bristol-Myers Squibb Leukemia Therapeutics Basic Information List
Table Bristol-Myers Squibb Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure Bristol-Myers Squibb Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2018)
Figure Bristol-Myers Squibb Leukemia Therapeutics Sales Market Share (%) in Korea (2013-2018)
Figure Bristol-Myers Squibb Leukemia Therapeutics Revenue Market Share (%) in Korea (2013-2018)
Table Eisai Leukemia Therapeutics Basic Information List
Table Eisai Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure Eisai Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2018)
Figure Eisai Leukemia Therapeutics Sales Market Share (%) in Korea (2013-2018)
Figure Eisai Leukemia Therapeutics Revenue Market Share (%) in Korea (2013-2018)
Table Biogen Idec Leukemia Therapeutics Basic Information List
Table Biogen Idec Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure Biogen Idec Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2018)
Figure Biogen Idec Leukemia Therapeutics Sales Market Share (%) in Korea (2013-2018)
Figure Biogen Idec Leukemia Therapeutics Revenue Market Share (%) in Korea (2013-2018)
Table ERYtech Pharma Leukemia Therapeutics Basic Information List
Table ERYtech Pharma Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure ERYtech Pharma Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2018)
Figure ERYtech Pharma Leukemia Therapeutics Sales Market Share (%) in Korea (2013-2018)
Figure ERYtech Pharma Leukemia Therapeutics Revenue Market Share (%) in Korea (2013-2018)
Table Celgene Leukemia Therapeutics Basic Information List
Table Celgene Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure Celgene Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2018)
Figure Celgene Leukemia Therapeutics Sales Market Share (%) in Korea (2013-2018)
Figure Celgene Leukemia Therapeutics Revenue Market Share (%) in Korea (2013-2018)
Table Genmab Leukemia Therapeutics Basic Information List
Table Genmab Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure Genmab Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2018)
Figure Genmab Leukemia Therapeutics Sales Market Share (%) in Korea (2013-2018)
Figure Genmab Leukemia Therapeutics Revenue Market Share (%) in Korea (2013-2018)
Table Cephalon Leukemia Therapeutics Basic Information List
Table Cephalon Leukemia Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
Figure Cephalon Leukemia Therapeutics Sales (K Units) and Growth Rate (%)(2013-2018)
Figure Cephalon Leukemia Therapeutics Sales Market Share (%) in Korea (2013-2018)
Figure Cephalon Leukemia Therapeutics Revenue Market Share (%) in Korea (2013-2018)
Table Clavis Pharma Leukemia Therapeutics Basic Information List
Table Pfizer Leukemia Therapeutics Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Leukemia Therapeutics
Figure Manufacturing Process Analysis of Leukemia Therapeutics
Figure Leukemia Therapeutics Industrial Chain Analysis
Table Raw Materials Sources of Leukemia Therapeutics Major Players/Manufacturers in 2017
Table Major Buyers of Leukemia Therapeutics
Table Distributors/Traders List
Figure Korea Leukemia Therapeutics Sales (K Units) and Growth Rate (%) Forecast (2018-2025)
Figure Korea Leukemia Therapeutics Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure Korea Leukemia Therapeutics Price (USD/Unit) Trend Forecast (2018-2025)
Table Korea Leukemia Therapeutics Sales (K Units) Forecast by Type (2018-2025)
Figure Korea Leukemia Therapeutics Sales (K Units) Forecast by Type (2018-2025)
Figure Korea Leukemia Therapeutics Sales Volume Market Share Forecast by Type in 2025
Table Korea Leukemia Therapeutics Sales (K Units) Forecast by Application (2018-2025)
Figure Korea Leukemia Therapeutics Sales Volume Market Share Forecast by Application (2018-2025)
Figure Korea Leukemia Therapeutics Sales Volume Market Share Forecast by Application in 2025

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *